MEDIAN TECHNOLOGIES (EGFF) (EIB-20180347)

Countries
  • France
Where the impacts of the investment may be experienced.
Financial Institutions
  • European Investment Bank (EIB)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Proposed
Bank Risk Rating
U
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Borrower
MEDIAN TECHNOLOGIES SA
The holder of the loan, grant, or other investment.
Sectors
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Loan
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 39.21 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Currency conversion note:
Bank reported EUR 35 million
Converted using 2019-05-14 exchange rate.
Loan Amount (USD)
$ 39.21 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Project Cost (USD)
$ 89.63 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.
Currency conversion note:
Bank reported EUR 80 million
Converted using 2019-05-14 exchange rate.
Primary Source

Original disclosure @ EIB website

Updated in EWS Jul 5, 2019

Disclosed by Bank May 14, 2019


Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description

According to EIB website, the project will finance Research & Development (R&D) investments made by Median Technologies, a French commercial-stage medtech company operating in the field of medical imaging in France and internationally. The EIB loan will contribute to finance (i) the recruitment of Artificial Intelligence experts, (ii) the creation of a proprietary data-base of patient history (iii) the clinical validation and regulatory approval of the software and algorithms and (iv) prepare the market access for the new business line. 

Investment Description
  • European Investment Bank (EIB)
Private Actors

Median Technologies SA develops and markets software products and platforms for medical image analysis in France and internationally. The company offers iBiopsy (Imaging BIOmarker Phenotyping System), a phenomics imaging platform that acquires, indexes, and analyzes various individual phenotypes and establish biological associations; and iSee for image analysis and management in clinical trials.

Contact Information

No contact information provided at the time of disclosure. 

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form, via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces